Conference
Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial.
Authors
Garcia AA; Oza AM; Hirte H; Fleming G; Tsao-Wei D; Roman L; Swenson S; Gandara D; Scudder S; Morgan R
Volume
23
Pagination
pp. 455S-455S
Publisher
AMER SOC CLINICAL ONCOLOGY
Publication Date
June 1, 2005
Name of conference
41st Annual Meeting of the American-Society-of-Clinical-Oncology
Conference place
FL, Orlando
Conference start date
May 13, 2005
Conference end date
May 17, 2005
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
16
ISSN
0732-183X